These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. What are the limits of adjuvanticity? Del Giudice G; Podda A; Rappuoli R Vaccine; 2001 Oct; 20 Suppl 1():S38-41. PubMed ID: 11587808 [TBL] [Abstract][Full Text] [Related]
24. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691 [TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells. Bonam SR; Platenburg PP; Bayry J Front Immunol; 2022; 13():1086752. PubMed ID: 36700217 [TBL] [Abstract][Full Text] [Related]
26. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. Chauhan N; Tiwari S; Iype T; Jain U Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554 [TBL] [Abstract][Full Text] [Related]
27. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348 [TBL] [Abstract][Full Text] [Related]
28. Novel Adjuvants and Immunomodulators for Veterinary Vaccines. Heegaard PM; Fang Y; Jungersen G Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830 [TBL] [Abstract][Full Text] [Related]
29. Squalene and squalane emulsions as adjuvants. Allison AC Methods; 1999 Sep; 19(1):87-93. PubMed ID: 10525443 [TBL] [Abstract][Full Text] [Related]
30. The use of oil adjuvants in therapeutic vaccines. Aucouturier J; Ascarateil S; Dupuis L Vaccine; 2006 Apr; 24 Suppl 2():S2-44-5. PubMed ID: 16823921 [TBL] [Abstract][Full Text] [Related]
31. Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4 Schmidt ST; Neustrup MA; Harloff-Helleberg S; Korsholm KS; Rades T; Andersen P; Christensen D; Foged C Pharm Res; 2017 Aug; 34(8):1716-1727. PubMed ID: 28516400 [TBL] [Abstract][Full Text] [Related]
32. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Dey AK; Srivastava IK Expert Rev Vaccines; 2011 Feb; 10(2):227-51. PubMed ID: 21105782 [TBL] [Abstract][Full Text] [Related]
33. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Süli J; Benísek Z; Eliás D; Svrcek S; Ondrejková A; Ondrejka R; Bajová V Vaccine; 2004 Sep; 22(25-26):3464-9. PubMed ID: 15308373 [TBL] [Abstract][Full Text] [Related]
34. The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value. Yang YW; Wei AC; Shen SS Vaccine; 2005 Apr; 23(20):2665-75. PubMed ID: 15780450 [TBL] [Abstract][Full Text] [Related]
40. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G; Barchfeld GL; Van Nest G Vaccine; 1995 Nov; 13(16):1557-62. PubMed ID: 8578842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]